Multipharma

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, large): better than 78% on solvency, 80% on liquidity, 40% on profitability and 83% on growth.

The bankruptcy probability was computed on 14-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).